Dr Reddy's Laboratories lost 2.65% to Rs 2,638.70 at 15:05 IST on BSE after consolidated net profit declined 56.61% to Rs 66.60 crore on 1.8% rise in total income to Rs 3371.20 crore in Q1 June 2017 over Q1 June 2016.
The announcement was made during market hours today, 27 July 2017.Meanwhile, the S&P BSE Sensex was up 12.88 points or 0.04% at 32,395.34
On the BSE, 76,000 shares were traded on the counter so far as against the average daily volumes of 32,560 shares in the past one quarter. The stock had hit a high of Rs 2,725 and a low of Rs 2,633.20 so far during the day. The stock had hit a 52-week high of Rs 3,516.95 on 26 July 2016 and a 52-week low of Rs 2,382.05 on 29 May 2017.
The stock had underperformed the market over the past one month till 26 July 2017, rising 2.12% compared with the Sensex's 4% rise. The stock also underperformed the market over the past one quarter, rising 4.52% as against the Sensex's 7.46% rise. The scrip, however, underperformed the market over the past one year, sliding 9.3% as against the Sensex's 15.75% rise.
The large-cap company has equity capital of Rs 82.91 crore. Face value per share is Rs 5.
Dr Reddy's Laboratories' consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) declined 15.56% to Rs 336 crore in Q1 June 2017 over Q1 June 2016. EBITDA margin contracted to 10.1% in Q1 June 2017, from 12.3% in Q1 June 2016.
Commenting on the results, Dr Reddy's Laboratories Co-Chairman and CEO G V Prasad said that while headwinds in the form of price erosion due to US customer consolidation continue, a lower contribution from new product launches in the US and GST implementation in India also impacted the company's performance.
Also Read
Dr Reddy's Laboratories is an integrated global pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content